RCE Technologies announced its groundbreaking advancements in its wearable-enabled biomarker studies at the 18th Annual Biomarker Symposium. The company presented its patented wearable device, Infrasensor, designed for gathering biochemical data.

The Infrasensor uses infrared technology in its operation. Being non-invasive, it aids in monitoring cardiac injury by providing real-time analysis paired with AI. The device was tested in a trial involving 840 individuals from 10 hospitals across the US. The device was used for three minutes while blood samples were gathered for biochemical analysis.

RCE Technologies specializes in developing non-invasive infrared-based wearable monitoring devices focusing on cardiovascular health. RCE Technologies' services are powered by its proprietary technology, including Infrasensor, which is a non-invasive transdermal device to measure cardiac conditions; infra-mind AI/ML platform that predicts heart attacks; and Infra-weave cloud service, which hosts, processes, and analyzes clinical and research data.